Genomics

Dataset Information

0

MYC family amplification dictates sensitivity to BET bromodomain protein inhibitor Mivebresib (ABBV-075) in small cell lung cancer


ABSTRACT: Small-cell lung cancer (SCLC) accounts for nearly 15% of all lung cancers. Although patients respond to first line therapy readily, rapid relapse is inevitable with few treatment options in the second line setting. Here, we describe SCLC cell lines harboring amplification of MYC and MYCN, but not MYCL1 nor non-amplified MYC cell lines, exhibit superior sensitivity to treatment with the pan-BET bromodomain protein inhibitor Mivebresib (ABBV-075). Silencing MYC and MYCN partially rescued SCLC cell lines harboring these respective amplifications from the anti-proliferative effects of mivebresib. Furthermore, the activity of mivebresib in SCLC cell lines occurs primarily through BRD2, rather than BRD4. Further characterization of genome-wide binding of MYC, MYCN, and MYCL1 uncovered unique enhancer and epigenetic preferences. Our study suggests that chromatin landscapes could establish cell states with unique gene expression programs, conveying sensitivity to epigenetic inhibitors such as mivebresib.

ORGANISM(S): Homo sapiens

PROVIDER: GSE230649 | GEO | 2024/07/31

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2011-12-08 | E-GEOD-29533 | biostudies-arrayexpress
2016-07-21 | E-GEOD-69393 | biostudies-arrayexpress
2016-07-21 | E-GEOD-69394 | biostudies-arrayexpress
2016-07-21 | GSE69394 | GEO
2016-07-21 | GSE69393 | GEO
2017-03-07 | GSE89934 | GEO
2010-06-10 | E-GEOD-22279 | biostudies-arrayexpress
2017-03-07 | GSE89933 | GEO
2017-03-07 | GSE89935 | GEO
2010-06-10 | GSE22279 | GEO